News | Atrial Fibrillation | September 24, 2015

ACC Launches Two Afib-Related Registry Programs

Registries to track ablation and left atrial appendage occlusion procedures

ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry

September 24, 2015 — The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world outcomes for the treatment and stroke prevention of patients with atrial fibrillation.

“With a growing prevalence of atrial fibrillation and growing options for treatment and stroke prevention in afib patients, the ACC saw a need for real-world data to track and evaluate the use of these new technologies,” said ACC President Kim A. Williams Sr., M.D., FACC. “Data derived from these registries are expected to inform practices and improve patient outcomes.”

In coming months, the ACC will launch the LAAO Registry, which will capture data on left atrial appendage occlusion procedures to assess real-world procedural indications and outcomes, as well as short- and long-term safety. Left atrial appendage occlusion procedures provide a treatment option to manage stroke risk for non-valvular atrial fibrillation patients who are unable to maintain adequate anticoagulation through medication therapy.

The college is also planning the AFib Ablation Registry to assess the prevalence, demographics, acute management and outcomes of patients undergoing atrial fibrillation ablation procedures. Its data will support the development of evidence-based guidelines and quality metrics for atrial fibrillation treatments that will improve outcomes for afib patients.

These two new clinical registry programs join eight other programs that comprise the National Cardiovascular Data Registry, the ACC’s suite of cardiovascular data registries that help hospitals and clinical practices measure and improve the quality of care they provide. 

For more information: www.acc.org


Related Content

News | Atrial Fibrillation

Feb. 9, 2026 — Argá Medtech has announced positive clinical results from the BURST-AF (NCT05572047) first-in-human trial ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Feb. 9, 2026 — Atraverse Medical presented new clinical and preclinical data at AF Symposium 2026 in Boston, further ...

Home February 09, 2026
Home
News | Atrial Fibrillation

Dec. 19, 2025 — Johnson & Johnson MedTech has announced its sponsorship of a new data collection platform developed by ...

Home December 19, 2025
Home
Feature | Atrial Fibrillation | Jeffrey Olgin, M.D.

Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable ...

Home September 12, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...

Home September 08, 2025
Home
News | Atrial Fibrillation

Sept. 8, 2025 — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders ...

Home September 08, 2025
Home
Feature | Atrial Fibrillation

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at elevated risk for cardiovascular disease.1 ...

Home September 04, 2025
Home
News | Atrial Fibrillation

June 13, 2025 — An international study has shown that targeted online education on atrial fibrillation (AF) for health ...

Home June 16, 2025
Home
News | Atrial Fibrillation

May 21, 2025 — Corify Care recently announced it has entered into a know-how agreement with Mayo Clinic. Corify Care is ...

Home May 22, 2025
Home
News | Atrial Fibrillation

April 25, 2025 – Medtronic plc, a global leader in healthcare technology, recently received U.S. Food and Drug ...

Home April 29, 2025
Home
Subscribe Now